Literature DB >> 19949357

Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas.

Chonnamet Techasaensiri1, Allison F Messina, Kathy Katz, Naveed Ahmad, Rong Huang, George H McCracken.   

Abstract

BACKGROUND: The heptavalent pneumococcal conjugate vaccine (PCV7) has significantly reduced vaccine-type invasive pneumococcal disease (IPD) in children. An increasing percentage of IPD cases are now caused by nonvaccine serotypes. The purpose of our observational study was to define the epidemiology of pneumococcal disease in Dallas, TX children for 8 years after implementation of PCV7 immunization.
METHODS: Streptococcus pneumoniae isolates from normally sterile sites were collected at Children's Medical Center of Dallas from January 1, 1999 to December 31, 2008. Incidence of IPD was calculated using inpatient and emergency center admissions to Children's Medical Center of Dallas as the denominator. Isolates were serotyped and penicillin and cefotaxime susceptibilities were determined. Serotype 19A isolates were further characterized by multilocus sequence typing.
RESULTS: Compared with the prevaccine period of 1999-2000, there was a significant reduction in the incidence of IPD from 2002 to 2008 (P < 0.05), although a significant increase in IPD incidence was observed from 2006 to 2008 (P = 0.038). The number of IPD cases caused by serotype 19A increased from 1999 to 2008 (P < 0.001). There were significant increases in penicillin and cefotaxime nonsusceptible 19A isolates during this 10-year period (P < 0.001 and P = 0.004, respectively). The most common sequence type (ST) of the 19A isolates was ST-199 (42.7%). Clonal complex (cc-156) and cc-320 emerged in the period of 2005-2008 as penicillin and cefotaxime resistant 19A strains.
CONCLUSIONS: In Dallas, PCV7 immunization reduced significantly the incidence of IPD caused by vaccine-type strains. A significant increase in IPD caused by serotype 19A was observed. The penicillin and cefotaxime nonsusceptible STs, not previously identified in Dallas, have recently become an important cause of IPD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19949357     DOI: 10.1097/INF.0b013e3181c2a229

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  19 in total

Review 1.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

2.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

3.  Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema.

Authors:  Anne J Blaschke; Caroline Heyrend; Carrie L Byington; Ignacio Obando; Isabel Vazquez-Barba; Elizabeth H Doby; E Kent Korgenski; Xiaoming Sheng; Mark A Poritz; Judy A Daly; Edward O Mason; Andrew T Pavia; Krow Ampofo
Journal:  Pediatr Infect Dis J       Date:  2011-04       Impact factor: 2.129

4.  Endocarditis with ruptured sinus of Valsalva aneurysm caused by nonvaccine Streptococcus pneumoniae serotype 21.

Authors:  Kamakshya P Patra; John A Vanchiere; Joseph A Bocchini; Amy C Wu; Robert D Jackson; Ernest A Kiel; Dennis Mello
Journal:  Tex Heart Inst J       Date:  2012

5.  Evolution of clonal and susceptibility profiles of serotype 19A Streptococcus pneumoniae among invasive isolates from children in Spain, 1990 to 2008.

Authors:  David Tarragó; Lorenzo Aguilar; Raquel García; María-José Gimenez; Juan-José Granizo; Asunción Fenoll
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 6.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

Review 7.  Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance.

Authors:  Rob J L Willems; William P Hanage; Debra E Bessen; Edward J Feil
Journal:  FEMS Microbiol Rev       Date:  2011-07-04       Impact factor: 16.408

8.  The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.

Authors:  David Cooper; Xinhong Yu; Mohinder Sidhu; Moon H Nahm; Philip Fernsten; Kathrin U Jansen
Journal:  Vaccine       Date:  2011-07-18       Impact factor: 3.641

9.  Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.

Authors:  Maria Leonor S Oliveira; Eliane N Miyaji; Daniela M Ferreira; Adriana T Moreno; Patricia C D Ferreira; Fernanda A Lima; Fernanda L Santos; Maria Aparecida Sakauchi; Célia S Takata; Hisako G Higashi; Isaías Raw; Flavia S Kubrusly; Paulo L Ho
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

10.  The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the 7-valent pneumococcal conjugate vaccine era: a case for continuous surveillance.

Authors:  Krow Ampofo; Andrew T Pavia; Stockmann Chris; Adam L Hersh; Jeffrey M Bender; Anne J Blaschke; Hsin Yi Cindy Weng; Kent E Korgenski; Judy Daly; Edward O Mason; Carrie L Byington
Journal:  Pediatr Infect Dis J       Date:  2012-03       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.